How a Novartis data platform is turning real-world evidence into actionable insights for urologists and oncologists.

A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.

Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.

Twenty-five years ago, Novartis pioneered a paradigm shift in cancer care with the introduction of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), transforming it from a deadly disease into a chronic condition for most patients. This breakthrough helped lay the foundation for targeted therapies in oncology and continues to shape the future of CML treatment today.

The creation of a 700,000-square-foot flagship manufacturing hub marks the continuation of our investment in the US, enabling us to more reliably reach patients across the country.

As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.

Learn how community-driven partnerships are helping to break down barriers and support access to health care.

Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.